

## Macrocyclic Ligands

## Gd-TEMDO: Design, Synthesis, and MRI Application\*\*

André Boltjes<sup>+</sup>,<sup>[a]</sup> Annadka Shrinidhi<sup>+</sup>,<sup>[a]</sup> Kees van de Kolk,<sup>[b]</sup> Eberhardt Herdtweck,<sup>[c]</sup> and Alexander Dömling<sup>\*[a]</sup>

To Ivar Ugi, the father of modern multicomponent reaction chemistry



Chem. Eur. J. 2016, 22, 7352 – 7356

Wiley Online Library



Abstract: A simple Ugi tetrazole multicomponent reaction allows the synthesis of a novel macrocyclic cyclen derivative with four appendant tetrazole arms in just two steps in excellent yields. This ligand, called TEMDO, turns out to have a high complexation affinity with lanthanoid metals. Here we describe the design, synthesis, solid-state structure, binding constant, and some MRI applications of the Gd-TEMDO complex as the first example of a congeneric family of oligo-amino tetrazoles.

Since its discovery in 1971, magnetic resonance imaging (MRI) has evolved into a major medical imaging technique and has rapidly found its way into daily clinical diagnostics.[1] Today, more than 20000 MRI scanners are operating in hospitals worldwide and more than 50 million clinical MRI examinations are performed every year. The impact of this breakthrough technology for mankind was honored by the Nobel Prize in Physiology or Medicine in 2003.<sup>[2]</sup> As opposed to other imaging techniques, MRI is a radiation-less method and is widely used in medical diagnosis and staging of disease. Although MRI does not, in principle, require contrast agents, their use dramatically accelerates acquisition times and signal intensity. MRI contrast agents work by accelerating the relaxation of water protons in the surrounding tissues. Paramagnetic ions are suitable contrast agents and, amongst them, gadolinium ( $Gd^{3+}$ ) complexes are by far the most widely used MRI contrast agents, owing to their seven unpaired electrons, slow electronic relaxation, and excellent complex stability. Although clinically approved MRI contrast agents are generally considered to be safe, a small number of fatalities were reported likely due to nephron- and neurotoxicity by Gd-leakage.<sup>[3]</sup> In addition, not only patients with pre-existing renal failure are affected by Gd-leakage, but also patients with other conditions showed considerable neuronal tissue concentrations of Gd<sup>3+</sup> after being subjected to Gd-based contrast agents (GBCAs).<sup>[4]</sup>

Here, we introduce the first example of the novel class of oligoamino tetrazoles as chelating agents useful in imaging: 1,4,7,10-tetrakis((1H-tetrazol-5-yl)methyl)-1,4,7,10-tetraazacyclo-

[a]	A. Boltjes, <sup>+</sup> Dr. A. Shrinidhi, <sup>+</sup> Prof. Dr. A. Dömling Department of Drug Design Groningen Research Institute of Pharmacy, University of Groningen A. Deusinglaan 1, Goroningen (The Netherlands)
[b]	E-mail: a.s.s.aomiing@rug.ni K. van de Kolk Central Animal Facility University of Groningen/UMCG A. Deusinglaan 50 (The Netherlands)
[c]	Dr. E. Herdtweck Institut für Anorganische Chemie Technische Universität München Lichtenbergstrasse 4, 85747 Garching bei München (Germany)
[+]	These authors contributed equally to this work.
[**]	TEMDO = 1,4,7,10-tetrakis((1H-tetrazol-5-yl)methyl)-1,4,7,10-tetraazacyclo dodecane.
06	Supporting information for this article is available on the WWW under

http://dx.doi.ora/10.1002/chem.201600720.



Scheme 1. DOTA, general formula of oligo-amino tetrazoles, TEMDO, and retro synthesis thereof. Pg = benzyl, *tert*-octyl.  $\beta$ -cyanoethyl.

dodecane (TEMDO, 3, see Scheme 1). We describe the design, synthesis, solid state structure, binding constant, and some MRI applications of the Gd-TEMDO complex.

The tetrazole is a known bioisostere of the carboxylic acid with often superior PKPD properties.<sup>[5]</sup> For example, the tetrazolate allows for a wider delocalization of the negative charge and could thus facilitate better penetration into tissue. In the context of MRI, a tetrazolate ligand could also help to increase proton relaxivity through changes in the metal-H distance by electron delocalization towards the ligand. Moreover, through subtle changes in the ligand composition and geometry eventually higher tilt angles between the plane of the bound water and the metal-O bond could be induced by hydrogen bonding of the coordinated water to an appropriate side group of the chelate, which could result in a significant decrease of the metal-proton distance. Thus, we reasoned that oligoamino tetrazoles are suitable for MRI, exhibiting different and potentially better physicochemical and biological properties compared to their carboxylic acid analogues. Surprisingly, oligoamino tetrazoles in general and specifically as MRI agents are unknown.<sup>[6]</sup> Based on our longstanding expertise in multicomponent reaction (MCR) chemistry and its versatility, speed and ease-to-perform, we choose MCR as a perfect tool to assemble this functional material class of MRI agents.<sup>[7]</sup> As a first synthetic target of the class of the oligoamino tetrazoles (2), we chose the tetrazole analogue (3) of DOTA<sup>[8]</sup> (1) (Scheme 1).

In our retrosynthesis, we envisioned that TEMDO can be fast and convergently synthesized by applying an Ugi tetrazole reaction from available cyclen.<sup>[9]</sup> The unprotected TEMDO ligand suitable for metal complexation has to be generated by cleavage of the isocyanide substituent. In principle, several cleavable isocyanides such as Walborsky's, benzyl-, or tert-butyl are suitable; however, we have chosen  $\beta$ -cyanoethyl isocyanide **4** here, owing to its mild cleavage conditions.

In fact, after some optimization of the reaction conditions we could obtain the Ugi tetrazole product 8 in quantitative yields by reacting the commercially available starting materials cyclen 5, paraformaldehyde 6, and TMS azide 7, as a safe hy-





Scheme 2. Two-step UT-MCR synthesis of the TEMDO ligand 3.

drogen azide source and  $\beta$ -cyanoethyl isocyanide **4** (Scheme 2). The four  $\beta$ -cyanoethyl groups can be cleaved under mild conditions using NaOH in acetonitrile/water at room temperature. The crude product was purified by precipitation at pH 7.75, to give neutral TEMDO ligand (86%) in high purity. Next, the chelating property of TEMDO towards the lanthanide element gadolinium was assessed. The Gd<sup>3+</sup> complex of TEMDO was prepared by either 1) heating the 1:1.1 mixture of TEMDO ligand and GdCl<sub>3</sub> in water at 70 °C for 7 days at pH 6.7, or by 2) heating TEMDO (in acidic form), the approved excipient meglumin, and GdCl<sub>3</sub> 1:1:1 in water for 7 days at 70 °C. The remaining free Gd<sup>3+</sup> was removed using ion-exchange resin Chelex<sup>®</sup>-100 and the clean liquid was lyophilized to get pure Gd-TEMDO complex (>98%) as a white bench-stable solid (Scheme 3).



Scheme 3. Reaction scheme of the formation of Gd-TEMDO complex; the counter ion sodium or meglumine is present depending on the method of preparation.

Then we investigated the complex behavior of TEMDO towards the lanthanide element gadolinium by determining its solid state 3D structure using X-ray crystallography. The complex crystallized in small rhombic shapes from water and the solved structure is shown in Figure 1. The side by side comparison of the obtained crystal structure of Gd-TEMDO with the Gd-DOTA complex shows a surprisingly high isosterism (Figure 1, and the video in the Supporting Information).

The central  $Gd^{3+}$  ion is surrounded by the four basal cyclen-N and apical by the four N1 of the appendant tetrazoles in



**Figure 1.** Comparison of the solid-state structure of Gd-DOTA (left column) and Gd-TEMDO (right column). Stick representation of the crystal structures (unbound crystal waters and counter-ions are omitted for clarity). Top row: top-down view; bottom row: side-on view.

a highly symmetrical twisted quadratic coordination sphere. In addition, a water molecule is coordinated on top of the twisted cube in-between the four tetrazole ligands. The coordination number for Gd<sup>3+</sup> is therefore 9 and the idealized complex belongs to the chiral point group C<sub>4</sub>. In principle, nine-fold coordinated Ln-complexes with C4 symmetry can present a square antiprismatic (SAP) or twisted square antiprismatic (TSAP) geometry. Moreover, owing to their membership of the chiral C<sub>4</sub> point group, Ln-TEMDO complexes can show the absolute chirality  $\Lambda$  (left-handed) or  $\Delta$  (right-handed). The coordination geometry of the Gd-TEMDO and Eu-TEMDO complexes is square antiprismatic (SAP), whereas in the La-TEMDO we have found twisted square antiprismatic (TSAP) geometry. For example, SAP geometry is the predominant form found for the Gd-DOTA complex in aqueous solution, besides some twisted square antiprism.<sup>[6a]</sup> Interestingly, the X-ray structures of the Gd- and Eu-TEMDO reveal only one SAP enantiomer per crystal, whereas La-TEMDO is present in a TSAP geometry and both  $\Lambda$  and  $\Delta$  enantiomers are present in one crystal (see the Supporting Information). Similarly, in Ln-DOTA complexes, SAP geometry is preferred over TSAP with increasing ionic lanthanide radius.<sup>[10]</sup> The complex geometry is an important parameter in MRI active Ln complexes as the water exchange kinetics are linked to its geometry and relaxivity.<sup>[11]</sup> Compared to TSAP, a SAP geometry will result in slower water exchange, but surprisingly a faster relaxation.<sup>[12]</sup> The comparable size of the macrocyclic cavity of DOTA and TEMDO indicates that suitable metal ions will very well fit to form thermodynamically stable chelates.<sup>[13]</sup> Qualitative assessment of free lanthanide ions with the indicator xylenol orange showed that chelating generally occurs for the lanthanides. In Table 1 we compare some key distances between Gd<sup>3+</sup> with DOTA and TEMDO and its coordination towards N and O in solid state. The similarity of the alignment between Gd<sup>3+</sup> and both DOTA and TEMDO expressed in distances gives an average difference of 0.09 Å



Table 1. M–O, M–N, and M–N' bond lengths in the 9-coordinated Gd-DOTA and TEMDO complexes.							
Complex	M—N [Å] <sup>[a]</sup>	M—O [Å] <sup>[b]</sup>	M—N′ [Å] <sup>[c]</sup>	M—O′ [Å] <sup>[d]</sup>			
[Gd(TEMDO)(H <sub>2</sub> O)] <sup>-</sup>	2.712	-	2.475	2.434			
[La(TEMDO)(H <sub>2</sub> O)] <sup>-</sup>	2.780	-	2.616	2.507			
[Gd(DOTA)(H <sub>2</sub> O)] <sup>-</sup>	2.648	2.377	-	2.458			

[a] N represents the basal rim nitrogen. [b] Metal coordination to the four surrounding carboxylates. [c] Metal coordination to the tetrazoles nitrogen N'. [d] Average distance between the metal and water molecule.

RMSD. Such minor changes in bond length and angle, however, can have profound effects on how well the ion is held, the residence time of the water molecule, and its exchange rate.<sup>[14]</sup>

The chelating properties of Gd-TEMDO were accessed by determination of the thermodynamic stability constant using colorimetry (Table 2).<sup>[15]</sup> The stability constant 16.6 confirms the strong chelating properties of the macrocyclic TEMDO, similar to Gd-(DTPA-BMA), a marketed MRI contrast agent (Omniscan, 16.8), though lower than Gd-DOTA. Studies on Gd<sup>3+</sup> release revealed that not only thermodynamic stability, but also kinetic inertness and elimination rate of the complex, plays an important role in the amount of free Gd<sup>3+</sup> in vivo.<sup>[12]</sup> Kinetic inertness expressed as dissociation rate is therefore important to predict toxicity through Gd<sup>3+</sup> leakage (Table 2). However, due to the general observed fast excretion of Gd-based contrast agents the complex is not long enough in the body to establish thermodynamic equilibrium. The lower stability constant of Gd-TEMDO as compared to the DOTA complex is thus compensated by a two orders of magnitude slower release of Gd<sup>3+</sup> from the TEMDO complex

Table 2. Binding constants and kinetic data of Gd <sup>3+</sup> complexes.								
Metal complex Log $K$ $k_{OH}$ $[M^{-1}s^{-1}]^{[a]}$		k <sub>OH</sub> [M <sup>-1</sup> s <sup>-1</sup> ] <sup>[a]</sup>	k <sub>H</sub> [M <sup>-1</sup> s <sup>-1</sup> ] <sup>[b]</sup>					
$[Gd(TEMDO)(H_2O)]^-$ $[Gd(DOTA)(H_2O)]^-$	16.6 24.1 <sup>[c]</sup>	$\begin{array}{c} 3.47 \pm 0.5 \times 10^{3} \\ 5.16 \pm 0.5 \times 10^{3} \end{array}$	$\begin{array}{c} 1.20 \pm 0.5 \times 10^{-8} \\ 3.20 \pm 0.5 \times 10^{-6} \end{array}$					
[a] Formation rate, experimentally determined for both TEMDO and DOTA by UV/VIS spectrometry. [b] Dissociation rate. [c] Value determined under identical conditions used for TEMDO (lit. value for Gd-DOTA 24.7; ref. [16]).								

Finally, we investigated the usefulness of Gd-TEMDO for magnetic resonance imaging. In a Bruker 9.4 T 400 MHz small bore MRI apparatus, we ran relaxation experiments resulting in phantom images of Gd-TEMDO (Figure 2). From the phantom images we calculated a relaxivity  $r_1$  of 2.0 mm<sup>-1</sup>s<sup>-1</sup>, which was lower than the Gd-DOTA value of  $6.0 \text{ mm}^{-1}\text{ s}^{-1}$  (measured under identical conditions at ambient temperature), but being in the same range a promising starting point for further introduction of variations on TEMDO. However, the  $T_1$ -weighted images, as expected, show a concentration-dependent increase of the relaxation rate of the solvent water protons associated



**Figure 2.** Gd-TEMDO MRI. a)  $T_1$ -weighted MRI phantoms of Gd-TEMDO proving concentration-dependent  $T_1$  shortening. b) MRI obtained from isoflurane-anaesthetized mice, c) taken 30 min after intraperitoneal injection (I.P.) of Gd-TEMDO (0.6 mmol kg<sup>-1</sup>). Left: the heart fully visible; right: heart with reduced brightness, the damaged tissue remains visible, owing to absorbed Gd-TEMDO following the red line.

with Gd-based contrast agents. In vivo assessment of Gd-TEMDO was performed through delayed contrast-enhanced MRI. Some Gd-based contrast agents such as Gd-DOTA accumulate in damaged myocardium tissues, diffusing from the intravascular into the interstitial space, unable to enter intact cells. Delay in measurement causes the majority of agent to wash out, and contrast agent absorbed in damaged tissue provides enhanced contrast.<sup>[17]</sup> In a left-coronary-artery occlusion murine animal model, we investigated Gd-TEMDO to image the myocardial infarcted tissue. This clearly shows that the TEMDO contrast agent is absorbed in damaged tissue and the enhanced contrast is shown in Figure 2.

In summary, we have described design, synthesis, X-ray structure, binding and some applications of the first example of a new class of Ln chelators with potential for use in MRI as Gd-based contrast agents. The macrocyclic TEMDO ligand is easy accessible by only two synthetic steps, in excellent yields employing a Ugi tetrazole multicomponent reaction. The thermodynamic stability constant of our first Gd<sup>3+</sup> complex is comparable to clinically used Gd-(DTPA-BMA). So far we were able to grow diffractable crystals of the  $\mathsf{Gd}^{\shortparallel},\ \mathsf{Eu}^{\shortparallel}$  and  $\mathsf{La}^{\shortparallel}$  complexes. Moreover we were able to show proof-of-principle, utilizing the Gd-TEMDO complex as contrast agent and visualizing myocardial infarcts in mice. Further analysis of the complex confirms comparable structural features as compared to marketed Gd-based contrast agents, a very good starting point for future development of this new class of oligotetrazolo-based metal complexes.

## **Experimental Section**

For details, see the Supporting Information.

All animal experiments were performed in accordance with the national guidelines on animal care and with prior approval by the Animal Experimentation Committee of University of Groningen.

Chem	Fur I	2016	22	7352 - 7356	
Chenn.	Lui. J.	2010,	<b>ZZ</b> ,	/ 552 - / 550	

www.chemeurj.org



## Acknowledgements

We want to thank Prof. Petr Vanura, Department of Analytical Chemistry, Institute of Chemical Technology, Prague, Czech Republic for providing computer programs LTGW ETITR and LTGW-SPEFO and helpful discussions. This work was financially supported from the NIH (1R01M097082-01).

**Keywords:** gadolinium • macrocyclic ligands • magnetic resonance imaging • multicomponent reactions • oligoamino tetrazole

- L. Helm, A. S. Merbach, E. Tóth, The chemistry of contrast agents in medical magnetic resonance imaging, 2nd ed., Wiley, Chichester, 2013.
- [2] a) P. C. Lauterbur, Angew. Chem. Int. Ed. 2005, 44, 1004–1011; Angew. Chem. 2005, 117, 1026–1034; b) P. Mansfield, Angew. Chem. Int. Ed. 2004, 43, 5456–5464; Angew. Chem. 2004, 116, 5572–5580.
- [3] P. Hermann, J. Kotek, V. Kubicek, I. Lukes, Dalton Trans. 2008, 3027– 3047.
- [4] R. J. McDonald, J. S. McDonald, D. F. Kallmes, M. E. Jentoft, D. L. Murray, K. R. Thielen, E. E. Williamson, L. J. Eckel, *Radiology* 2015, 275, 772–782.
- [5] R. J. Herr, Bioorg. Med. Chem. 2002, 10, 3379-3393.
- [6] a) S. Aime, M. Botta, M. Fasano, M. P. M. Marques, C. F. G. C. Geraldes, D. Pubanz, A. E. Merbach, *Inorg. Chem.* **1997**, *36*, 2059–2068; b) A. Dömling, (Patentscope) Vol. WO/2015/117626, **2015**.

- [7] a) A. Dömling, Chem. Rev. 2006, 106, 17–89; b) A. Dömling, W. Wang, K. Wang, Chem. Rev. 2012, 112, 3083–3135; for an example of cyclen derivatization by Ugi reaction, see: c) M. Main, J. S. Snaith, M. M. Meloni, M. Jauregui, D. Sykes, S. Faulkner, A. M. Kenwright, Chem. Commun. 2008, 5212–5214.
- [8] a) H. Stetter, W. Frank, Angew. Chem. Int. Ed. Engl. 1976, 15, 686; Angew. Chem. 1976, 88, 760; b) J. F. Desreux, Inorg. Chem. 1980, 19, 1319– 1324.
- [9] I. Ugi, C. Steinbruckner, Chem. Ber. 1961, 94, 734-742.
- [10] M. Meyer, V. Dahaoui-Gindrey, C. Lecomte, L. Guilard, Coord. Chem. Rev. 1998, 178, 1313 – 1405.
- [11] M. Milne, K. Chicas, A. Li, R. Bartha, R. H. E. Hudson, Org. Biomol. Chem. 2012, 10, 287–292.
- [12] S. Avedano, M. Botta, J. S. Haigh, D. L. Longo, M. Woods, *Inorg. Chem.* 2013, *52*, 8436–8450.
- [13] R. Delgado, V. Felix, L. M. P. Lima, D. W. Price, *Dalton Trans.* 2007, 2734–2745.
- [14] W. P. Cacheris, S. K. Nickle, A. D. Sherry, Inorg. Chem. 1987, 26, 958-960.
- [15] Z. Baranyai, E. Gianolio, K. Ramalingam, R. Swenson, R. Ranganathan, E. Brucher, S. Aime, *Contrast Media Mol. Imaging* 2007, *2*, 94–102.
- [16] M. Reková, P. Vaňura, V. Jedináková-Křížová, The Open Inorganic Chemistry Journal 2009, 3, 26–32.
- [17] S. Bohl, C. A. Lygate, H. Barnes, D. Medway, L. A. Stork, J. Schulz-Menger, S. Neubauer, J. E. Schneider, Am. J. Physiol. Heart Circ. Physiol. 2009, 296, H1200-H1208.

Received: February 16, 2016 Published online on April 8, 2016